title: [Clinical and pharmacological factors related to the requirements of laser photocoagulation in patients with diabetic nephropathy due to type 2 diabetes mellitus].
abstract: OBJECTIVE
  Diabetic retinopathy is a microvascular complication of diabetes mellitus whose prevalence is closely related to the presence of nephropathy and hypertension. The aim was to study clinical and pharmacological factors that are associated with an increased need for laser photocoagulation in patients with diabetic nephropathy and retinopathy.
  
  
  METHODS
  Cross sectional study of 63 patients followed in the Diabetic Nephropathy consultation. Patients were divided into 2 groups according to whether or not previously have received photocoagulation. In each subgroup were studied demographic variables, anthropometric, laboratory, cardiovascular risk factors and treatment received by each patient for the control of hypertension, diabetes and others diseases.
  
  
  RESULTS
  We observed that the group had received photocoagulation had more years of diabetes evolution, more history of cardiovascular disease and a lower creatinine clearance. Similarly, the percentage of patients treated with carvedilol was significantly higher in the subgroup who had not received photocoagulation while the percentage of patients treated with beta-blockers was significantly higher in the subgroup that received photocoagulation; no significant differences was observed in the degree of control blood pressure.
  
  
  CONCLUSIONS
  Clinical and pharmacological factors related to the requirements of laser photocoagulation were years of diabetes evolution, history of cardiovascular disease, the stage of kidney disease and the treatment with beta-blockers.
authors.affiliation: Servicio de Nefrología, Hospital Insular Universitario de Gran Canaria, Las Palmas, España. ingrid_auyanet@hotmail.com
authors.forename: Ingrid
authors.initials: I
authors.lastname: Auyanet
authors.forename: Luis Javier
authors.initials: LJ
authors.lastname: Rodríguez
authors.forename: Luis José
authors.initials: LJ
authors.lastname: Rodríguez
authors.forename: Ana Yurena
authors.initials: AY
authors.lastname: Sánchez
authors.forename: Noemi
authors.initials: N
authors.lastname: Esparza
authors.forename: Francisco
authors.initials: F
authors.lastname: Cabrera
authors.forename: Elvira
authors.initials: E
authors.lastname: Bosch
authors.forename: Pedro
authors.initials: P
authors.lastname: Cardona
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Checa
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000453:epidemiology; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D003928:Diabetic Nephropathies / Q000150:complications* / Q000453:epidemiology; D003930:Diabetic Retinopathy / Q000150:complications / Q000453:epidemiology / Q000601:surgery*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000453:epidemiology; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D017075:Laser Coagulation / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin